Entinostat deal expands Eddingpharm's China oncology portfolio

Following a string of deals this year by Chinese pharma firms looking to license in technology and products from foreign partners, the Hong Kong-based drug marketing company Eddingpharm has acquired rights in China and several other Asian markets to Syndax Pharmaceuticals' lead candidate entinostat.